Phua Kong Boo, Tee Nancy, Tan Nancy, Ramakrishnan Gunasekaran, Teoh Yee-Leong, Bock Hans, Liu Yanfang
From the Departments of *Pediatrics and †Pathology and Laboratory Medicine, KK Women's and Children's Hospital, Singapore; ‡GlaxoSmithKline Pharmaceuticals Pvt Ltd, India; §Emergent BioSolutions; and ¶GlaxoSmithKline Vaccines Pvt Ltd, Singapore.
Pediatr Infect Dis J. 2013 Dec;32(12):e426-31. doi: 10.1097/INF.0b013e31829f2cb0.
In Singapore, 2 rotavirus vaccines were licensed in October 2005 and July 2007, respectively, for vaccinating infants aged ≥ 6 weeks against rotavirus gastroenteritis. These vaccines are optional and are not included in the National Childhood Immunization Program. This study aimed to determine the incidence of rotavirus gastroenteritis-associated hospitalizations among children <5 years of age.
Children <5 years, who were hospitalized for acute gastro enteritis, were enrolled between September 2005 and April 2008. Stool samples were tested for the presence and serotyping of rotavirus. Incidence and proportion of gastroenteritis and rotavirus gastroenteritis cases were calculated with 95% confidence intervals.
Among 1976 children included in the according-to-protocol cohort, 781 were rotavirus positive with a median age of 24 months (range: 0-59 months). The overall incidence of rotavirus gastroenteritis hospitalizations during the entire study period in children <5 years of age was 4.6 (95% confidence interval: 4.3-4.9) per 1000 person-years with the highest number of cases observed in children 13-24 months of age (26.5%). G1P[8] (18.3%) and G9P[8] (9.9%) were the most common rotavirus types. Rotavirus gastroenteritis hospitalizations peaked between January and March.
Rotavirus infection was the primary cause of acute gastro enteritis hospitalizations among children <5 years of age, constituting nearly one-third of gastroenteritis hospitalizations in Singapore. The predominant strain observed in Singapore was G1P[8]. Results of this study suggest the need for implementation of rotavirus vaccination into National Childhood Immunization Program in Singapore.
在新加坡,两种轮状病毒疫苗分别于2005年10月和2007年7月获得许可,用于为6周龄及以上婴儿接种以预防轮状病毒肠胃炎。这些疫苗为非强制性疫苗,未纳入国家儿童免疫规划。本研究旨在确定5岁以下儿童中与轮状病毒肠胃炎相关的住院发病率。
纳入2005年9月至2008年4月期间因急性肠胃炎住院的5岁以下儿童。检测粪便样本中轮状病毒的存在及血清型。计算肠胃炎和轮状病毒肠胃炎病例的发病率及比例,并给出95%置信区间。
在符合方案队列中的1976名儿童中,781名轮状病毒检测呈阳性,中位年龄为24个月(范围:0 - 59个月)。在整个研究期间,5岁以下儿童轮状病毒肠胃炎住院的总体发病率为每1000人年4.6例(95%置信区间:4.3 - 4.9),其中13 - 24个月龄儿童的病例数最多(26.5%)。G1P[8](18.3%)和G9P[8](9.9%)是最常见的轮状病毒类型。轮状病毒肠胃炎住院病例在1月至3月达到高峰。
轮状病毒感染是5岁以下儿童急性肠胃炎住院的主要原因,在新加坡几乎占肠胃炎住院病例的三分之一。在新加坡观察到的主要毒株是G1P[8]。本研究结果表明新加坡有必要将轮状病毒疫苗接种纳入国家儿童免疫规划。